BMT - Beamtree Holdings

[Dona Ferentes]

... just needs to get to 44 before I become real interested.

would a close of 46.5c at day's end (twice; Th & Fr) do?

 

[Country Lad]

would a close of 46.5c at day's end (twice; Th & Fr) do?

Yes

 

[Dona Ferentes]

The Company proposes to change its name from PKS Holdings Limited to Beamtree Holdings Limited which more suitably reflects the proposed future operations of the Company and its global presence.

And a ticker change to BMT

Motion got up at EGM. change a-coming.

With the recent acquisition of Pavilion Health, the suite of software products now consists of:
● RippleDown® enables any clinical domain expert – typically a pathologist or clinician – to automate their unique, human decision-making process at scale in order to provide real-time clinical analysis, interpretations and treatment recommendations. By aggregating and analysing all available patient information – including current and historical results – RippleDown® is able to provide a holistic view of patients to generate the most comprehensive and patient-specific interpretations and recommendations.
● RippleDown® is managed by domain experts, not IT, enabling rules to be built quickly and easily to ensure the system remains updated and relevant.
● PICQ® is an auditing tool used in hospitals that assesses every record clinically coded for data quality. It measures data accuracy against indicators and identifies records for correction and uses a set of pre-determined indicators created and maintained by PKS’ subject-matter experts to identify records that may be incorrectly coded.
● RISQTM Reviews records in datasets to assess the quality of Condition Onset Flags (COF) data and incidences of hospital-acquired complications (HACs). It provides a method to benchmark hospitals against statistical peers to provide industry benchmarks of HAC incidence and underlying data quality.
● CodexpertTM is a web-based eBook application providing the full health-data classification reference for clinical coding of patient episodes.

steadily a-building. Now 54c; an all time high.

 

[Dona Ferentes]

PKS is pleased to advise that following shareholder approval at the Company’s Extraordinary General Meeting held on 17 August 2021, the name of PKS Holdings Limited has changed to Beamtree Holdings Limited.

In accordance with ASX’s notice protocol, it is expected that the new ticker code, BMT and company name, will be effective on the ASX from the commencement of trading on Friday 20 August

 

[System]

On August 20th, 2021, PKS Holdings Limited (PKS) changed its name and ASX code to Beantree Holdings Limited (BMT).

 

[Dona Ferentes]

Beamtree (formerly PKS Holdings) (ASX: BMT) and The University of Sydney today announce a five-year collaboration to establish a global centre of excellence in health data research that will support improved patient outcomes and develop next generation data tools and applications.

The Beamtree and University of Sydney collaboration will see the first senior academic appointment in clinical informatics in Australia - the Beamtree Associate Professor of Clinical Informatics. The appointment will lead a new research team in the Faculty of Medicine and Health at The University of Sydney to innovate in the use of health data so that cutting edge approaches to biomedical informatics and AI can support sustainable, high-quality health care around the world.

“This partnership is an international milestone in promoting best use of health data using new analytic methodologies and AI technologies. We are delivering a vital public service mission – continuously innovating in how we can best serve health services around the world with next generation knowledge management,” said Tim Kelsey, CEO of Beamtree.

Beamtree will provide a five-year funding commitment of up to $250,000 per annum to cover costs associated with the position. Beamtree will leverage the partnership to ensure new knowledge arising from the research supports product development and ambitions to improve healthcare outcomes.

 

[Dona Ferentes]

and the market likes this acquisition; up 30% this morning at the start ...now 25%

HIGHLIGHTS

• Beamtree has entered into a binding agreement to acquire 100% of the shares in Potential(x) Holdings Pty Ltd, a complementary and market leading specialist health & human services data analytics firm.
• The acquisition will materially increase the scale, capability and global customer reach of Beamtree. On a pro-forma basis FY21 Revenue is circa $20m of which is 82% is recurring. The Beamtree team will more than double to 110+.
• The acquisition is fully funded and on attractive terms for Beamtree shareholders, with consideration to Potential(x) shareholders comprising up to 30m shares in Beamtree and $4m cash consideration. This implies an enterprise value for Potential(x) of $19.6m on a debt free, cash free basis (1.8x F21 revenue and 7.4x FY21 operational EBITDA).
• Potential(x)’s Managing Director and majority shareholder, Duane Attree, will join Beamtree’s executive team and become a substantial shareholder. Potential(x) shareholders will own 9.6% of Beamtree. Management and the Board of Beamtree will own 34% of the company.
• The acquisition increases Beamtree’s pro-forma FY21A EBITDA by 86% with only 9.6% dilution to existing Beamtree shareholders

 

[Dona Ferentes]

and BMT was doing so well, skirmishing 70 for a few days, until

A block of 5,000,000 went through at 58c XT, and any thoughts of mid to high 60s are lost

 

[Dona Ferentes]

and BMT was doing so well, skirmishing 70 for a few days, until ... a block of 5,000,000 went through at 58c XT, and any thoughts of mid to high 60s are lost

And from that early Sept high, Beamtree has gone as low as 50c yesterday

An announcement today has seen renewed interest, with a rally to 58c. A pity that occurred prior to the 10:39 release.

Beamtree is pleased to announce a strategic partnership with the Central Adelaide Local Health Network (CALHN). The partnership will see the implementation of RISQ TM (data quality product) across the CAHLN network of hospitals, the launch of a new trial using RippleDown® (AI decision support product) and the Ainsoff Index (which is used for early detection of deteriorating patients), and the opportunity to co-develop a new implementation of RippleDown® in clinical workflow.

 

[Dona Ferentes]

And from that early Sept high, Beamtree has gone as low as 50c yesterday

still stuck around that level, around 50c. There have been no announcements in the last month and only one Market Sensitive one in 3 months. The company is probably busy digesting the latest acquisition.

From the October AGM:
Over the next few months, the Beamtree and Potential(x) teams will continue to work on the post-merger integration. The strategic objectives of the merger are to:
• Accelerate growth in new global markets and adjacent sectors
• Add value and market access for existing solutions and software
• Reduce barriers to entry in ANZ market (immediate market share, expertise and insight into public hospital sector)
• Grow our people, leadership, industry and technical expertise
• Be cash flow positive and profitable
• Integration of Potential(x) analytics and insights into other software and markets

So. something might happen, though if they are working with pathology and hospials, I'd reckon any discussions would be brief and decisions even harder to close.

 

[Dona Ferentes]

still stuck around that level, around 50c. There have been no announcements in the last month and only one Market Sensitive one in 3 months. The company is probably busy digesting the latest acquisition.

From the October AGM:

and the Half Year numbers are out. Ditto to above. 45c is the new black.

when the talk is of Adelaide, Sth island NZ, Saudi, a S African contract.... it seems these digitisation, workflow solutions need to be tested in the provinces. The big players have their own systems, and won't jump. Will they, ever?

 

[Dona Ferentes]

and BMT was doing so well, skirmishing 70 for a few days, until
..... A block of 5,000,000 went through at 58c XT, and any thoughts of mid to high 60s are lost

and the broad tech, early growth sell-off took no prisoners. got to sub 30c recently

BMT announces its first NHS contracts with four leading hospital trusts in England to drive improvements in patient care.

These are the first international clients for Beamtree’s proprietary RippleDown® decision support technology in hospital-based care – Beamtree is already an international market leader in applications of decision support in pathology. It is also the first time that Beamtree coding and analytic services have been contracted in England.

Combined annual revenue of these partnerships is around £300,000 (approximately $540,000 AUD). These first phase agreements are expected to lead to multi-year engagements. Although the estimated revenue is not financially material, the partnerships are considered to be strategically important to the Company. There are no material conditions that need to be satisfied before the parties become legally bound to proceed with the terms of the contract / proof of concept.

 

[Dona Ferentes]

BMT announces a material five-year contract worth US$7m (AU$9.7m) or US$1.4m annually with Ampath, a leading provider of pathology services in South Africa for the provision of its RippleDown® decision support product.

.... up 12% from where they were in 2020, at a low of 25.5c.

RippleDown® is BMT’s proprietary software which automates clinical and administrative process in healthcare, in pathology. RippleDown® reduces the time pathologists spend reading routine test results and improves the quality of data entry to drive financial efficiency.
The partnership with Ampath, which currently works with around 40% of South Africa’s private healthcare sector, follows a successful proof-of-concept pilot that examined how RippleDown® can help Ampath laboratories drive the best pathology services, better healthcare, safety and value for money.

The pilot report showed that Beamtree’s RippleDown® Expert technology could automate up to 90% of clinical interpretations which could prove an estimated saving of over 6,000 hours per annum of manual validation. Additional savings of up to 40,000 hours per annum of administrative time could be achieved with the RippleDown® Auditor functions.

 

[Dona Ferentes]

I presume the latest Announcement is to 'remind' investors of their suite of products, During the recent sell-off of tech stocks and anything on Price to Sales rather than more substance of PE or other measures, BMT tapped as low as 25c early May. Now 35c

Our Products (with latest milestone updates on each provided in the Ann.)
Beamtree provides automation technology and data analytics that support health care providers to improve safety, increase effectiveness and reduce the administrative burden on clinical staff. The four key product categories include:
1. Diagnostic technology: powered by our flagship RippleDown® software products which automate expert decision making in clinical and administrative processes in pathology;
2. Coding Automation and data quality: our RippleDown® and PICQ® coding technologies improve data quality in health services, and are now using AI to develop new approaches to the automation of clinical record coding;
3. Clinical decision support: our suite of Ainsoff applications leverage RippleDown® with machine learning to transform patient safety through automation of clinical and administrative processes; and
4. Analytics and knowledge networks: we are field leaders in using data to benchmark quality and financial efficiency through national and global peer-to-peer alliances that accelerate innovation and knowledge management.

• New contract wins since the start of 2022 worth $16m total contract value and around $3.0m per annum in revenue over the next 12 months.
• Accelerated international growth with sales of products and capabilities in the period, with Beamtree’s services now operating in more than 20 countries.

And as they say; The impact of these achievements will not materially impact financial performance in the current financial year but will impact future years.

(H)

 

[Dona Ferentes]

FY22 Financial Highlights
• Delivery of +97% year on year growth in group revenue to $16.55m.
• Reported ARR (Annual recurring revenue) as end of FY22 is +$18.2M, which represents a +171% year on year growth.
• Organic ARR (excluding Potential(x) acquisition) year on year growth is +30% driven by new contract wins in 2H FY22.
• Organic international revenue grew by 14% year on year. • Recurring revenue exceeding 92% of total group revenue.
• Strong cash balance of $6.3M as of 30 June 2022 ($7.0M as of 31 Dec 2021) with significant reduction in cash burn in 2H FY22 leading into FY23.

.... still trying to work out if it's all going to happen.. .. whilst there is "strong demand for our products and services by our healthcare clients, in need of best-practice data and decision support technologies" the continual " focus on product development and signing on clients globally over the next year” is a cost; and is it a treadmill?

(Do hold; paid less than what I could get, but the 'tech sell-off' was painful. Now 28c)

 

[Dona Ferentes]

Outlook for FY23

In relation to the new financial year to 30 June 2023, the Board expects the following trends to drive the performance of the Company:

Revenue
• July 2022 trading conditions remain positive with like for like sales up 17% on the prior year.
• Total reported revenue growth target of ~35% in FY23.
• Sales pipeline continues to build particularly the International sales pipeline which is significantly larger versus prior year.
• International diagnostics expected to be the main driver of revenue growth in FY23.
• Pilot projects in Europe moving toward contract stage expected to boost 2H FY23.
• Aiming to conclude contract extension discussions with Abbott Laboratories in 1H23.

Margin
• Revenue product mix in FY23 expected to drive improved gross margin.
• International scale and increasing contract value expected to contribute to increased gross margin.

Operating expenses and cash
• Operating expenses to be carefully managed in FY23.
• Significant investment made in FY22 via acquisitions and investment in international growth strategy.
• Cost base in FY23 to remain stable outside of international growth aspirations.
• Targeted large scale contract wins will drive operational leverage.
• It is expected that benefits will flow from cost efficiency synergies as a result of acquisitions made in FY22.
• Move to operating cashflow positive in FY23.

 

[Dona Ferentes]

subsidiary Beamtree UK Limited announces a key strategic partnership with Lean, Saudi Arabia’s leading provider of innovative health solutions.

The agreement of this strategic partnership follows the successful completion of Beamtree’s first major contract to support data transformation in public health services of the hospital network data analytics audit for the Kingdom of Saudi Arabia. Beamtree is pleased to extend our ability to provide further products and services into Saudi via this strategic partnership with Lean.

Beamtree has now received full payment for phase 1 of the data transformation project of US$1.45m (AU$2m). The next phase is the proposed implementation of Beamtree’s products across Ministry of Health hospitals and then more broadly across public and private hospital networks (over 450 hospitals in total).

 

[Dona Ferentes]

AGM comments seemed to have helped BMT recover some of the "tech and growth sell off" negativity that has been in the market for most of 2022.

Outlook Re-affirmed with Strong Operating Momentum across all Four Segments
• As outlined above, Beamtree continues to deliver strong revenue growth with local and international organic growth opportunities.
• The sales pipeline, particularly for international sales of our core products (RippleDown®, ADI™ and PICQ®), remains very strong with the company focused on finalizing procurement on many of these new customers in FY23.
• Beamtree continues to manage its costs carefully through this high growth period. It remains committed to balancing continued demand-driven delivery for its products against its working capital needs.
• Beamtree re-affirms its reported revenue growth target of ~35% in FY23 and moving towards being operating cash flow positive in FY23.

 

[Dona Ferentes]

It's gone and done a 'Jake the Peg' on me. I had held since the PKS days and made a bit on the way up and down . Recently sold out at 30c and then it puts on an extra spurt, on no news.

 

[Knobby22]

Noticed the volume.
Director buying.
I did read a book that showed that making decisions on people's health using a program like this appears to give better healthcare results as it removes various biases.

My pick for the month.